Comparative Pharmacology
Head-to-head clinical analysis: LASTACAFT versus NAPHCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASTACAFT versus NAPHCON A.
LASTACAFT vs NAPHCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
Naphcon-A combines naphazoline, an alpha-adrenergic receptor agonist, and pheniramine, a histamine H1-receptor antagonist. Naphazoline constricts conjunctival blood vessels via alpha-adrenergic stimulation, reducing redness and edema. Pheniramine blocks histamine effects, alleviating itching and allergic reactions.
1 drop in each affected eye twice daily (approximately every 8 hours)
1-2 drops instilled into the conjunctival sac every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Naphazoline: ~2-3 hours; antazoline: ~3-4 hours. Clinical context: ocular administration, systemic absorption minimal.
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Primarily renal excretion of unchanged drug and metabolites; naphazoline <10% unchanged, antazoline ~30% unchanged. Biliary/fecal elimination negligible.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine/Decongestant